Search Results
Nov 05, 2025, 16:05 ET Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
with dabogratinib at 50 mg once-daily (QD) (Cohort 1) or treatment with dabogratinib at 60 mg QD (Cohort 2). The primary endpoint is complete response (CR) rate at three months. Secondary endpoints include time to recurrence, median duration of response, recurrence free survival, progression free survival,
More news about: Tyra Biosciences
Nov 05, 2025, 12:57 ET Piramal Pharma Limited Announces Results for Q2 and H1 FY26
(in ₹ Cr. or as stated)
More news about: Piramal Pharma Limited
Nov 05, 2025, 09:13 ET CRUNCH FITNESS FRANCHISEE CELEBRATES MILESTONE 10-YEAR ANNIVERSARY OF CRUNCH BRADENTON
About CR Fitness Holdings, LLC CR Fitness Holdings, LLC is the leading franchisee of Crunch Fitness, and led by a management team with over 150 years of combined experience in the fitness industry. CR Fitness is on track to operate
More news about: CR Fitness Holdings, LLC.
Nov 05, 2025, 09:03 ET CRUNCH FITNESS FRANCHISEE CELEBRATES MILESTONE 10-YEAR ANNIVERSARY OF CRUNCH JOHNS CREEK
About CR Fitness Holdings, LLC CR Fitness Holdings, LLC is the leading franchisee of Crunch Fitness, and led by a management team with over 150 years of combined experience in the fitness industry. CR Fitness is on track to operate
More news about: CR Fitness Holdings, LLC.
Nov 04, 2025, 07:30 ET Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition,
More news about: Actinium Pharmaceuticals, Inc.
Nov 03, 2025, 09:15 ET CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
comprising 4 patients who achieved CR (2 MCL, 2 DLBCL) and 1 patient who achieved PR (DLBCL). Focusing on the 6e8 cell dose, 6 patients were enrolled. Four of them were evaluable for efficacy, and 3 achieved a response, all of which were CR. The remaining 2 DLBCL patients had
More news about: CARsgen Therapeutics
Nov 03, 2025, 09:05 ET Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
in patients with prior intensive chemotherapy (IC), the ORR was 50% with 35/105 (33%) achieving CR and 38/105 (36%) achieving CR/CRh. Median DOR was 15.5 months, with median duration of CR not reached and CR/CRh of 17.6 months. After a median follow up of 37.3 months, the median
More news about: Rigel Pharmaceuticals, Inc.
Nov 03, 2025, 09:03 ET Crunch Fitness Franchisee CR Fitness Holdings Makes Waves in Pompano Beach with Plans for New Club Opening
Carolina, Texas, and Tennessee, with plans to expand into Arizona. About CR Fitness Holdings, LLC CR Fitness Holdings, LLC is the leading franchisee of Crunch Fitness, with over 150 years of combined experience in the
More news about: CR Fitness Holdings, LLC.
Nov 03, 2025, 09:00 ET Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting
enzomenib was escalated from 40 mg twice a day (BID) to 400 mg BID with no dose-limiting toxicities (DLTs) in 116 patients with sustained complete remission (CR) and complete remission with partial hematologic recovery (CRh) seen at doses of 200, 300 and 400 mg BID. Given the wide therapeutic window of enzomenib,
More news about: Sumitomo Pharma America
Nov 03, 2025, 08:30 ET Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition,
More news about: Actinium Pharmaceuticals, Inc.
Oct 30, 2025, 07:35 ET Knight Therapeutics anuncia la aprobación y el lanzamiento de MINJUVI® (tafasitamab) en Argentina
análisis primario demostraron una tasa de respuesta objetiva (ORR, criterio de valoración primario) del 60 %, incluida una tasa de respuesta completa (CR) del 43 % y una tasa de control de la enfermedad (DCR) del 74 %2,3. Según las directrices de la National Comprehensive Cancer Network (NCCN)
More news about: Knight Therapeutics Inc.
Oct 29, 2025, 14:46 ET Dykema's National White Collar and Government Investigations Group Secures Complete Dismissal of Federal Indictments in Texas and Maryland in 48-Hour Period
of Maryland. In the District of Maryland Greenbelt Division - United States v. Wang, case no. 8:24-cr-00211-TDC-1: Last Thursday, Dykema secured a rare trial-stage victory when the U.S. Department of Justice dismissed—with
More news about: Dykema
Oct 29, 2025, 05:44 ET CB Insights recognizes Wonderlend Hubs as one of the most promising fintech startups of 2025
Product and Risk Management to Revenue Operations, to adapt quickly, experiment often, and scale with confidence. We process Rs. 6,500+ Cr. incentive payouts and Rs. 8500+ Cr. loans, helping our clients achieve true digital transformation at scale." Wonderlend's inclusion underscores
More news about: Wonderlend Hubs
Oct 29, 2025, 03:00 ET Star Health Reports 21% YoY Profit Growth to ₹518 Cr; COR Improves by 170 bps in H1FY26 under IFRS
robust bancassurance and financial institution partners, and 14,700+ employees. In FY25, Star Health's gross written premium stood at Rs.16,781 Cr with its net worth at Rs.8,668 Cr. For more information visit www.starhealth.in
More news about: Star Health and Allied Insurance
Oct 28, 2025, 14:52 ET North Castle Partners Named to Inc. Magazine's Top Founder-Friendly Private Equity Firms For its Fifth Consecutive Year
with the founder CEO to more than double its capacity to help young adults and teens overcome mental health and substance use disorders. Most recently, CR Fitness Holdings, a North Castle portfolio company, attained a strategic growth investment from a global investment firm to support the company's future
More news about: North Castle Partners, L.L.C.
Oct 28, 2025, 08:35 ET Hanyang University Researchers Explore Role of Time-Restricted Eating in Controlling MASLD
group, or the control group; the calorie restriction (CR) group; and the TRE group. Improvement in hepatic steatosis and changes in physical, physiological, and biochemical parameters were analyzed. Participants in both the TRE and CR groups showed a significant decrease in hepatic
More news about: Hanyang University
Oct 27, 2025, 23:01 ET "METALEX 2025" अगली पीढ़ी की मशीनरी पर प्रकाश डालने के लिए तैयार | ASEAN धातुकर्म को स्मार्ट विनिर्माण की ओर अग्रसर करना
नैनोमीटर-स्तर मापने वाला उपकरण, पहली बार थाईलैंड में पेश किया गया।NACHI MZS05 – स्मार्ट सेंसर से सुसज्जित बुद्धिमान कोबोट।Dobot CR30H - हाई-स्पीड पैलेटाइजिंग रोबोट। और भी कई अत्याधुनिक नवाचार जो विनिर्माण प्रदर्शन को अगले स्तर तक ले जाएंगे।
More news about: METALEX
Oct 27, 2025, 10:05 ET Kelley Blue Book Introduces "Fork in the Road: Drive & Dine Guide"
Honda CR-V (2026)
More news about: Kelley Blue Book
Oct 27, 2025, 07:00 ET Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition,
More news about: Actinium Pharmaceuticals, Inc.
Oct 24, 2025, 08:30 ET Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a Phase 2/3 trial. In addition, Actinium
More news about: Actinium Pharmaceuticals, Inc.
Oct 24, 2025, 08:13 ET "METALEX 2025" Ready to Spotlight Next-Generation Machinery | Driving ASEAN Metalworking Toward Smart Manufacturing
measuring instrument, first introduced in Thailand.NACHI MZS05 – Intelligent cobot equipped with smart sensors.Dobot CR30H – High-speed palletizing robot. And many more cutting-edge innovations that will elevate manufacturing performance
More news about: METALEX
Oct 24, 2025, 04:40 ET Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website
showed that regardless of patient baseline characteristics, iza-bren could bring consistent and stable high response rates. Notably, complete response (CR) cases were observed in the iza-bren group, demonstrating its excellent ability to clear tumor lesions[1],[2]. The
More news about: eChinaHealth
Oct 23, 2025, 06:15 ET Innoviti Posts 35% Revenue Growth in FY25
Operating revenue grew by 35% from Rs. 106 Cr. in FY25 to Rs. 143 Cr. FY26. Gross margins grew by 44% from Rs. 84 Cr. in FY25 to Rs. 121 Cr. in FY26. EBITDA loss (inclusive of Rs. 4 Cr. ESOP cost) reduced from -29% to -17%.
More news about: Innoviti Technologies Pvt. Ltd.
Oct 22, 2025, 14:37 ET A&G Named 'Real Estate Advisor of the Year' in Turnaround Atlas Awards
transportation and mobility services provider Coach USA, later acquired by affiliates of The Renco Group. Heading the larger restructuring effort were CR3 Partners, LLC, as well as investment banker Houlihan Lokey and debtor's counsel Alston & Bird and Young Conaway Stargatt & Taylor, LLP.
More news about: A&G Real Estate Partners
Oct 22, 2025, 07:39 ET Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
72.2% of patients achieving complete response or stringent complete responses (CR/sCR). Among the seven patients who had received prior BCMA-directed CAR T-cell therapy, the ORR was 85.7%, with 5 patients (71.4%) achieving CR/sCR. All three patients with extramedullary disease and the patient with pPCL achieved
More news about: IASO Bio